Annovis Bio Inc
ANVS
Company Profile
Business description
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
Contact
101 Lindenwood Drive
Suite 225
MalvernPA19355
USAT: +1 484 875-3192
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
6
Stocks News & Analysis
stocks
Progress in UK expansion for undervalued ASX share
Guidance reaffirmed and UK implementation on track.
stocks
The sectors set to soar on government spending
Governments worldwide love to spend more money, and there are no signs that it will change any time soon.
stocks
Chart of the Week: How private companies are reshaping public markets
Our latest take from the US Manager Research team.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,065.70 | 11.20 | -0.12% |
| CAC 40 | 7,964.77 | 109.46 | -1.36% |
| DAX 40 | 23,734.02 | 315.72 | -1.31% |
| Dow JONES (US) | 46,912.30 | 398.70 | -0.84% |
| FTSE 100 | 9,735.78 | 41.30 | -0.42% |
| HKSE | 26,283.52 | 202.38 | -0.76% |
| NASDAQ | 23,053.99 | 445.80 | -1.90% |
| Nikkei 225 | 49,888.48 | 995.20 | -1.96% |
| NZX 50 Index | 13,647.43 | 70.62 | 0.52% |
| S&P 500 | 6,720.32 | 75.97 | -1.12% |
| S&P/ASX 200 | 8,801.50 | 9.00 | -0.10% |
| SSE Composite Index | 4,000.06 | 7.70 | -0.19% |